Ignite Creation Date:
2024-05-06 @ 2:29 AM
Last Modification Date:
2024-10-26 @ 11:19 AM
Study NCT ID:
NCT02055846
Status:
TERMINATED
Last Update Posted:
2015-06-25
First Post:
2012-10-26
Brief Title:
Analysis of the Mechanisms of Actions of Heat Shock Protein Hsp27 Responsible of the Androgen-independent Evolution in Prostate Cancer
Sponsor:
Institut Paoli-Calmettes
Organization:
Institut Paoli-Calmettes
Study Overview
Official Title:
Analysis of the Mechanisms of Actions of Hsp27 Responsible of the Androgen-independent Evolution in Prostate Cancer
Status:
TERMINATED
Status Verified Date:
2012-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Insufficient biological material for analysis
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Prostate cancer PC represents one of the most common cancers in industrialized countries Patients with localized disease may be treated with surgery or radiation while androgen ablation is used as first-line therapy in patients with metastatic disease While most patients initially respond well to this hormonal therapy they most ultimately become unresponsive and recur within 2 years as androgen-independent prostate cancer AIPC Recently docetaxel-based regimens have demonstrated improved survival in men with AIPC in two different large phase III studies However the median overall survival was prolonged for only 2 or 3 months Androgen independent AI progression involves variable combinations of clonal selection adaptive up-regulation of anti-apoptotic genes ligand-independent androgen receptor AR activation alternative growth factor pathways and immune system escape Additional therapeutic strategies targeting molecular mechanisms mediating resistance combined with immunotherapy must be developed One strategy to improve therapies in advanced PC involves targeting genes that are activated by androgen withdrawal either to delay or prevent the emergence of the resistant AI phenotype Recently a scientistidentified Heat Shock Protein Hsp27 as a highly over-expressed gene in AIPC Hsp27 knockdown using antisens oligonucleotides ASO and small interfering RNA siRNA increased apoptotic rates and enhanced hormone- and chemo-therapy in PC She developed and patented a 2nd generation ASO targeting Hsp27 that has been licensed investigational drug called OGX-427 and clinical trials phase III is currently in process in PC Despite OGX-427 efficiency the functional role of stress induced Hsp27 in castration or chemotherapy-induced apoptosis remains undefined The purpose of this study is to elucidate the pathways leading to Hsp27 action in androgen-independent prostate cancer in order to 1 Increase the pharmacological safety of OGX-427 and 2find new specific therapeutic targets and treatment strategy for androgen-independent prostate cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None